Novel Peptide Shows Promising Biophysical Properties for Inhaled Lung Therapy
Background
The phosphoinositide 3-kinase gamma (PI3Kγ) pathway plays a crucial role in regulating inflammation and immune responses within the lungs. Modulating cAMP (cyclic adenosine monophosphate), a key intracellular signaling molecule, in pulmonary cells offers a therapeutic avenue for various respiratory diseases. However, achieving targeted and efficient delivery of modulators to specific lung pathways remains a significant challenge. This study addresses the lack of a precisely characterized peptide for inhaled delivery that specifically targets the A-kinase anchoring function of PI3Kγ to modulate pulmonary cAMP.
Results
The PULMO-Modulin peptide demonstrated favorable biophysical properties, forming stable nanoparticles with an average hydrodynamic diameter of 150 nm. Aerodynamic assessment revealed an optimal mass median aerodynamic diameter of 2.8 µm, with a fine particle fraction of 62%, suggesting efficient deep lung deposition. The peptide exhibited excellent stability, retaining 95% of its integrity after 24 hours at 37°C in simulated lung fluid. In A549 lung epithelial cells, treatment with PULMO-Modulin resulted in a significant 2.3-fold increase in intracellular cAMP levels compared to untreated control cells (p<0.001). This cAMP modulation was observed without significant cytotoxicity, with cell viability remaining above 90% at the tested concentration. Furthermore, the peptide showed a 1.8-fold higher affinity for PI3Kγ compared to other PI3K isoforms, indicating good specificity.
Why It Matters
This research provides critical foundational data for developing PULMO-Modulin as a potential inhaled therapeutic for pulmonary diseases where cAMP modulation is beneficial, such as asthma or COPD. The favorable biophysical and aerodynamic properties suggest it could be efficiently delivered directly to the lungs, potentially minimizing systemic side effects. The demonstrated ability to specifically modulate cAMP via PI3Kγ inhibition opens new avenues for targeted lung therapies. These findings strongly support advancing PULMO-Modulin towards in vivo efficacy studies and eventually human clinical trials for respiratory conditions.